Market Trends of Global RNA-interference (RNAi) Industry
This section covers the major market trends shaping the RNA-interference (RNAi) Market according to our research experts:
Oncology is Expected to Hold Significant Market Share in the Therapeutics Type
The oncology segment is expected to hold a significant market share during the forecast period.
The increasing incidence of cancer among the global population leading to the rise in demand for effective therapeutics is expected to drive the growth of the studied segment. As per the report of the International Agency for Research on Cancer published GLOBOCAN 2020 report, there were an estimated 19,292,789 new cases of cancer diagnosed in 2020 and about 9,958,133 people died due to cancer, all over the world. As per the same source, of the total diagnosed cancer cases, 10,065,305 cases were reported in males and 9,227,484 cases were reported in females. the incidence of cancer cases in males was expected to reach 15,585,096 by 2040 and 13,302,846 in females by 2040. Such an increasing incidence of cancer among the global population is expected to drive the growth of the market.
Recent advancements, such as the development of small interfering RNA (siRNA) tolerant to nucleases and the development of non-viral vectors, such as cationic liposomes and nanoparticles, can overcome this obstacle and facilitate the clinical use of RNAi-based therapeutics in the treatment of cancer. Substantial pipeline for cancer therapies by companies and institutes such as Enzon Pharmaceuticals (Santaris Pharma), University of Texas, OncoGenex, Isarna Therapeutics, Astrazeneca (Ionis Pharmaceuticals), and INSYS Therapeutics, Inc. are expected to drive the market. For instance, In December 2021, Novartis received United States Food and Drug Administration approval for Leqvio, the small interfering RNA (siRNA) therapy for low-density lipoprotein with two doses a year, after an initial dose and one at three months. In addition, many companies have invested in R&D for nanocarriers to deliver oligonucleotides for cancer treatment, which is expected to contribute to the oncology verticle.
Thus the above mentioned factors are expected to drive the growth of the studied segment during the forecast period.
North America Dominates the Market and Expected to do the Same in the Forecast Period
North America is expected to provide lucrative opportunities for the growth of the market owing to the rising incidence of target diseases and growing demand for advanced therapeutics and diagnostics. For instance, according to the American Cancer Society's report in 2022 over 1.9 million new cancer cases are expected to be diagnosed in the United States 2022. and additionally, 80% of the people diagnosed with cancer in the United States are 55 years of age or older and 57% are 65 or older Thus, due to the high prevalence of cancer, and the rising affected geriatric population, the demand for diagnostics and treatment is also high in the country which is expected to drive the growth in the studied market in the United States.
The United States has a number of RNAi therapeutics that are in developmental pipelines. A number of biotechnology companies have made considerably high investments for RNAi therapeutic development. key pharmaceutical developers have entered into collaboration agreements or licensing deals with a number of smaller firms in an attempt to capitalize on the expected growth in revenue that this market can have over the forecast period. For instance, in Dember 2021, AstraZeneca's agreement with Ionis pharmaceuticals is one of the big deals that are investing heavily into RNA-interference technology. The increasing approvals for the RNAi therapy is expected to drive the growth of the market during the forecast period. For instance in December 2021 , Novartis received United States Food and Drug Administration approval for Leqvio, the first and only small interfering RNA (SiRNA) therapy to low- density lipoprotein with two doses a year, after an initial dose and one at three months.
Thus the above mentioned factors are expected to drive the growth of the market in the studied region.
